By Dr.S.N. Gupta

Peyronie’s disease (PD) is an acquired fibrotic disorder of the penile tunica albuginea that frequently coexists with erectile dysfunction (ED), with up to 60% of men with PD reporting some degree of erectile impairment. Rather than being separate conditions, PD and ED increasingly are understood as overlapping manifestations of a shared “vascular–fibrotic” penile pathology driven by endothelial dysfunction, oxidative stress, inflammation, and transforming growth factor–β1 (TGF-β1)–mediated fibrosis. This article synthesizes current understanding of how PD induces or exacerbates ED, the mechanisms linking the two, diagnostic approaches, and evidence-based management strategies.academic.oup+2

What is Peyronie’s disease?

Peyronie’s disease is characterized by the formation of fibrous plaques within the tunica albuginea surrounding the corpora cavernosa. These plaques are non-elastic and do not expand normally during erection, leading to penile curvature, indentation or “hourglass” deformity, shortening, and sometimes painful erections. The condition typically progresses through two phases:pmc.ncbi.nlm.nih+2

• Acute (active) phase: Lasts roughly 6–18 months; marked by penile pain (often with erection), evolving curvature, and active plaque formation.pmc.ncbi.nlm.nih+1
• Chronic (stable) phase: Pain usually resolves; curvature and deformity stabilize, and plaques may calcify.pmc.ncbi.nlm.nih+1

PD affects an estimated 0.4%–13% of men, with higher prevalence in those aged 45–60, though it can occur in younger men and even teenagers. It is associated with comorbidities such as diabetes, hypertension, hyperlipidemia, smoking, and prior pelvic surgery (e.g., radical prostatectomy).pmc.ncbi.nlm.nih+2

How Peyronie’s disease leads to erectile dysfunction

ED in PD is multifactorial. It arises from a combination of mechanical, vascular, neurogenic, and psychological factors that often reinforce one another.

1. Mechanical and structural factors

• Curvature and deformity: Severe angulation, indentation, or hinge effect can physically prevent intromission or make intercourse painful, functionally manifesting as ED even if hemodynamics are intact.pmc.ncbi.nlm.nih+1
• Venous occlusive dysfunction: Fibrosis and plaque formation can impair the tunica’s ability to compress subtunical venules during erection, causing venous leak and inadequate rigidity. This is often the predominant hemodynamic mechanism of ED in PD.pmc.ncbi.nlm.nih+1
• Penile shortening and girth loss: Chronic fibrosis and scar contracture reduce effective penile length and girth, contributing to dissatisfaction and performance anxiety.clevelandclinic+1

2. Vascular and endothelial dysfunction

PD and vasculogenic ED share key pathophysiologic pathways:

• Endothelial nitric oxide synthase (eNOS) dysregulation: Microtrauma and inflammation reduce nitric oxide (NO) bioavailability, impairing smooth muscle relaxation and penile tumescence.academic.oup+1
• Oxidative stress: Reactive oxygen species (ROS) scavenge NO, promote lipid peroxidation, and activate profibrotic signaling.academic.oup+1
• Microvascular injury: Repetitive microtrauma to the erect penis initiates localized inflammation, fibrin deposition, and subsequent fibrosis, paralleling processes seen in generalized vasculogenic ED.academic.oup+1

These mechanisms create a vicious cycle: endothelial injury promotes fibrosis; fibrosis worsens hemodynamics; poor hemodynamics further injures endothelium.academic.oup+1

3. Fibrotic remodeling and extracellular matrix (ECM) dysregulation

TGF-β1 is a central mediator in PD plaque formation. It drives fibroblast-to-myofibroblast differentiation, increases collagen I/III deposition, and suppresses matrix metalloproteinases (MMPs), favoring ECM accumulation. Similar fibrotic pathways are implicated in corporal tissue changes in chronic ED, particularly in diabetes and post-prostatectomy states. Over time, this leads to reduced tissue compliance and impaired expansion of the corpora cavernosa.academic.oup+2

4. Psychological and relational factors

The visible deformity, pain, and sexual difficulties associated with PD often cause significant psychological distress:

• Performance anxiety and fear of rejection: Men may avoid sexual activity due to embarrassment or concern about partner reaction.pmc.ncbi.nlm.nih+1
• Depression and reduced self-esteem: Studies report high rates of depression and relationship strain in men with PD.pmc.ncbi.nlm.nih
• Partner impact: Partners may experience reduced desire or satisfaction, further compounding sexual dysfunction.academic.oup

Psychological ED can precede, accompany, or follow the onset of physical symptoms, making comprehensive assessment essential.pmc.ncbi.nlm.nih+1

Epidemiology and clinical overlap

• Up to 60% of men with PD report concomitant ED.academic.oup+1
• Among men presenting with ED, approximately 8%–10% have clinically or ultrasonographically detectable PD.academic.oup
• ED severity does not always correlate with curvature degree; some men with mild curvature have significant ED due to vascular or psychological factors, while others with severe deformity maintain good erections.academic.oup+1

This overlap necessitates routine screening for ED in all PD patients and for tunical abnormalities in men with refractory or unexplained ED.academic.oup+1

Diagnostic evaluation

A thorough evaluation integrates history, physical exam, validated questionnaires, and targeted imaging.

History and symptom assessment

Key elements include:

• Onset, duration, and progression of curvature or deformity.
• Presence and timing of penile pain (flaccid or erect).
• Erectile function: ability to achieve/maintain erection sufficient for intercourse.
• Psychosocial impact: anxiety, depression, relationship issues.
• Comorbidities: diabetes, cardiovascular disease, smoking, prior pelvic surgery.pmc.ncbi.nlm.nih+1

Validated tools:

• International Index of Erectile Function (IIEF-15) or Erection Hardness Score (EHS) for ED.pmc.ncbi.nlm.nih+1
• Peyronie’s Disease Questionnaire (PDQ) for PD-specific symptoms and bother.academic.oup

Physical examination

• Palpation for plaques (location, size, consistency).
• Assessment of penile length (stretched and, if possible, erect).
• Evaluation of curvature direction and severity.
• Check for associated fibroproliferative disorders (e.g., Dupuytren’s contracture).pmc.ncbi.nlm.nih+1

Imaging and functional testing

• Penile duplex Doppler ultrasound (PDDU): First-line imaging to visualize plaques, detect calcification, and assess arterial inflow and venous occlusion after intracavernosal injection.academic.oup+1
• Ultrasound elastography: Emerging tool to quantify plaque stiffness and monitor treatment response.academic.oup
• MRI: Reserved for complex cases (e.g., basal plaques, suspicion of malignancy).academic.oup
• Endocrine and metabolic labs: Testosterone, prolactin, HbA1c, lipid profile to identify reversible contributors.academic.oup+1

Disease staging

Distinguishing active vs. stable phase guides therapy:

• Active phase: Pain, progressive curvature → medical/injection therapies preferred.
• Stable phase: Fixed deformity, no pain → surgical or mechanical interventions considered.pmc.ncbi.nlm.nih+1

Management strategies

Treatment is individualized based on disease phase, curvature severity, erectile function, penile length, and patient goals. A multimodal approach targeting both fibrosis and vascular function yields the best outcomes.

1. Pharmacologic therapy

Phosphodiesterase type 5 inhibitors (PDE5is)

• Mechanism: Enhance NO–cGMP signaling, improve penile hemodynamics; may also exert antifibrotic effects by inhibiting myofibroblast transformation.academic.oup+1
• Evidence: Observational data suggest PDE5is (e.g., sildenafil, tadalafil) may reduce pain, improve erectile function, and possibly slow curvature progression in active PD, though randomized trial data are limited.academic.oup+1
• Clinical use: First-line for mild-to-moderate ED in PD; often combined with other therapies.academic.oup+1

Antioxidants and antifibrotics

• Pentoxifylline: Non-specific phosphodiesterase inhibitor with antioxidant and antifibrotic properties; may stabilize or modestly improve curvature, especially in early disease.academic.oup+1
• Vitamin E, L-carnitine, CoQ10: Commonly used but with inconsistent evidence; CoQ10 showed some benefit in a randomized trial (improved IIEF, plaque area, curvature).academic.oup+1
• Limitations: Overall evidence for oral agents is weak; guidelines do not strongly endorse most.pmc.ncbi.nlm.nih+1

Hormonal therapy

• Testosterone replacement: Considered in hypogonadal men; may improve libido and PDE5i response, but data specific to PD are inconclusive.academic.oup

2. Intralesional injection therapy

Direct injection into plaques achieves high local drug concentrations with minimal systemic effects.

Collagenase Clostridium histolyticum (CCH; Xiaflex)

• Mechanism: Enzymatically degrades type I and III collagen in plaques.pmc.ncbi.nlm.nih+1
• Evidence: IMPRESS trials showed ~34% average curvature reduction and improved sexual function in men with stable PD, curvature 30°–90°, and preserved erectile function.academic.oup+1
• Protocol: Up to 4 treatment cycles; each cycle includes two injections 1–3 days apart, followed by penile modeling.pmc.ncbi.nlm.nih
• Limitations: Less effective for ventral plaques or severe calcification; risk of penile pain, bruising, swelling.pmc.ncbi.nlm.nih

Verapamil and interferon-α2b

• Verapamil: Calcium channel blocker; inhibits fibroblast proliferation and ECM production. Modest improvements in plaque size and curvature, especially in non-calcified, smaller plaques (<2.5 cm) and early disease.pmc.ncbi.nlm.nih+1
• Interferon-α2b: Antifibrotic cytokine; demonstrated ~55% plaque size reduction and ~27% curvature improvement in one study.pmc.ncbi.nlm.nih+1
• Side effects: Flu-like symptoms (interferon), local pain/ecchymosis (both).pmc.ncbi.nlm.nih+1

Hyaluronic acid (HA)

• Emerging option: EMA-approved in some regions; shown to reduce plaque size and improve curvature with good safety profile.academic.oup

3. Physical and mechanical therapies

Penile traction therapy (PTT)

• Mechanism: Sustained stretch promotes collagen remodeling, reduces fibrosis, and may preserve or increase length.academic.oup+1
• Evidence: Studies report improvements in curvature, stretched length, and girth, especially with daily use (3–8 hours) over months.pmc.ncbi.nlm.nih+1
• Use: Adjunct in active or stable PD; also valuable post-surgery for rehabilitation.academic.oup+1

Vacuum erection devices (VED)

• Similar principles to PTT; may improve pain, length, and curvature.pmc.ncbi.nlm.nih
• Often combined with PDE5is or intralesional therapy.academic.oup

Low-intensity extracorporeal shockwave therapy (Li-ESWT)

• Mechanism: Promotes angiogenesis, reduces pain, and may aid tissue remodeling.academic.oup+1
• Evidence: Consistently improves penile pain in active PD; effects on curvature are less clear.pmc.ncbi.nlm.nih

4. Surgical management

Surgery is reserved for stable disease with significant deformity preventing intercourse or refractory ED.

Penile shortening procedures (plication/Nesbit)

• Indication: Curvature <60°, adequate penile length, good erectile function.pmc.ncbi.nlm.nih+1
• Technique: Sutures or wedge resection on the convex (longer) side to straighten the penis.pmc.ncbi.nlm.nih
• Outcomes: High straightening rates (>80%); main risk is penile shortening (1–1.5 cm).pmc.ncbi.nlm.nih

Penile lengthening procedures (plaque incision/excision with grafting)

• Indication: Curvature >60°, hourglass deformity, or concern for excessive shortening.pmc.ncbi.nlm.nih+1
• Graft materials: Autologous (vein, dermis), allograft (cadaveric pericardium), xenograft (porcine SIS), or synthetic.pmc.ncbi.nlm.nih
• Risks: Postoperative ED (up to 25%–60%), graft contracture, recurrent curvature.pmc.ncbi.nlm.nih+1

Penile prosthesis implantation (PPI)

• Indication: PD with moderate-to-severe ED refractory to PDE5is, or severe deformity with poor erectile function.onlinelibrary.wiley+1
• Approach: Inflatable or malleable prosthesis, often combined with straightening maneuvers (manual modeling, plication, grafting).onlinelibrary.wiley+1
• Outcomes: High patient and partner satisfaction (>80%); reliably restores rigidity and corrects curvature.onlinelibrary.wiley+1
• Special considerations: Manual modeling carries small risk of urethral injury; grafting may be needed for residual curvature >30°.pmc.ncbi.nlm.nih

5. Regenerative and emerging therapies

• Stem cell therapy (e.g., adipose-derived stem cells): Preclinical data show inhibition of fibrosis and promotion of tissue regeneration; human trials are ongoing.pmc.ncbi.nlm.nih+1
• Exosome and gene-targeted therapies: Early-stage research targeting TGF-β, Wnt/β-catenin, and other fibrotic pathways.academic.oup+1
• AI-assisted diagnostics: Emerging tools for automated plaque detection and progression prediction.academic.oup

Psychological and partner-inclusive care

Given the profound psychosocial impact of PD-induced ED:

• Screening: Routine assessment for anxiety, depression, and relationship distress.academic.oup+1
• Counseling: Cognitive-behavioral therapy (CBT), sex therapy, and partner-inclusive counseling improve adherence and satisfaction.academic.oup+1
• Education: Addressing misconceptions (e.g., “PD is untreatable” or “only affects the elderly”) encourages early presentation and treatment.pmc.ncbi.nlm.nih+1

Practical clinical algorithm

A simplified approach to managing PD with ED:

1. Assess disease phase (active vs. stable) and erectile function (IIEF/EHS).
2. Active phase + mild ED: PDE5i ± pentoxifylline/antioxidants; consider intralesional therapy (CCH, verapamil, interferon) and/or PTT/VED.
3. Stable phase + preserved erections: Intralesional CCH (if eligible) or surgical straightening (plication/grafting) based on curvature severity.
4. Stable phase + significant ED: Penile prosthesis implantation with adjunctive straightening as needed.
5. Throughout: Address psychological factors, optimize comorbidities (diabetes, lipids, smoking cessation), and involve partners in care.